Association between drug interactions and polymedication of patients with acute myocardial infarction in a hospital from Rio Grande do Sul
DOI:
https://doi.org/10.5902/2236583485394Keywords:
Myocardial infarction, Risk factors, Pharmacological treatment, Elderly healthAbstract
Objective: To evaluate medications, potential drug interactions, and polypharmacy in patients who have had acute myocardial infarction, and to verify the association of polypharmacy with risk factors. Methods: This was a cross-sectional, descriptive and analytical study conducted at the Institute of Cardiology of a High Complexity Hospital in Southern Brazil. Data were collected between May and December 2017. Patients admitted to the hospital with ST-segment elevation myocardial infarction were included. The outcome variables were: Medication used to identify drug interactions and use of polypharmacy and risk factors for cardiovascular diseases such as smoking, alcoholism, dyslipidemia, diabetes mellitus (DM), systemic arterial hypertension (SAH), family history of cardiovascular disease (FH). Results: 191 patients participated in the research. It was found that 52% of prescriptions contained at least one potential drug interaction, with 89% of potential interactions considered moderate and 11% severe. Polypharmacy was correlated with FH (p = 0.025), DM (p = 0.047), SAH (p≤0.001) and Drug Interaction (p≤0.001). Final considerations: Polypharmacy is associated with diabetes, hypertension, and a family history of cardiovascular disease.
Downloads
References
World Health Organization. Cardiovascular diseases (CVDs) [Internet]. Geneva: WHO; 2025 [citado em 25 jun 2026]. Disponível em: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Malta DC, Teixeira R, Oliveira GMM, Ribeiro ALP. Mortalidade por doenças cardiovasculares segundo o Sistema de Informação sobre Mortalidade e as estimativas do Estudo Carga Global de Doenças no Brasil, 2000-2017. Arq Bras Cardiol. 2020;115(2):152-160. doi:10.36660/abc.20190867.
Lloyd-jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al; American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586-613.
Ministério da Saúde. DATASUS - 2014. [Cited em 05 oct 2019]. Disponível em: http://datasus.saude. gov.br
Rocha RM. Epidemiologia das doenças cardiovasculares e fatores de risco. In: Rocha RM, Martins WA, editores. Manual de prevenção cardiovascular. São Paulo: Planmark; Rio de Janeiro: SOCERJ; 2017. p. 10-15.
Chaves G, Britez N, Munzinger J, Uhlmann L, Gonzales G, Oviedo G, et al. Education to a healthy lifestyle improves symptoms and cardiovascular risk factors: AsuRiesgo Study. Arq Bras Cardiol. 2015;104(5):347-55.
Secoli, SR, Figueras A, Lebrão ML, de Lima FD, Santos JLF. Risk of Potential Drug-Drug Interactions among Brazilian Elderly. Drugs & Aging. 2010;27(9):759–770.
Ramos LR, Tavares NUL, Bertoldi AD, Farias MR, Oliveira MA, Luiza VL. Polifarmácia e polimorbidade em idosos no Brasil: um desafio em saúde pública. Rev. Saúde Pública. 2016;50(suppl 2)9s:1-13.
Vieira LB, Cassiani SHB. Avaliação da adesão medicamentosa de pacientes idosos hipertensos em uso de polifarmácia. Rev Bras Cardiol. 2014;27(3):195-202.
Secoli SR. Polypharmacy: interaction and adverse reactions in the use of drugs by elderly people. Revista Brasileira de Enfermagem. 2010;63(1):136-140.
Micromedex Healthcare Series. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc – 2007 [Internet]. [cited em 2 oct 2019] Disponível em: https://www.thomsonhc.com/hcs/librarian/
World Health Organization, Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical ATC/DDD Index, 2016 [Internet]. Geneva: WHO; 2016 [Cited em 23 oct 2016]. Disponível em: http://www.whocc.no/atc_ddd_index/.
Venturini CD, Engroff P, Ely LS, Zago LFA, Schroeter G, Gomes I, et al. Gender differences, polypharmacy, and potential pharmacological interactions in the elderly. Clinics. 2011;66(11):1867-72.
Avezum, Á, Piegas LS, Pereira JCR. Fatores de risco associados com infarto agudo do miocárdio na região metropolitana de São Paulo. Uma região desenvolvida em um país em desenvolvimento. Arq Bras Cardiol. 2005;84(3):206-13.
Castro ML. Infarto agudo do miocárdio. Arquivos Brasileiros de Cardiologia. 2009;93(6):132-137.
Piegas LS, Timerman A, Feitosa GS, Nicolau JC, Mattos LAP, AndradeMD, et al. V Diretriz da Sociedade Brasileira de Cardiologia sobre tratamento do infarto agudo do miocárdio com supradesnível do segmento ST. Arquivos brasileiros de cardiologia. 2015;105(2):1-121.
Silva, DT, Campos CAM, Vargas TG, Ziulkoski AL, Andrighetti LH, Perassolo MS.Possíveis interações medicamentosas em pacientes polimedicados de Novo Hamburgo, RS, Brasil. Infarma-Ciências Farmacêuticas. 2018;30(1):21-29.
Kovačević M, Vezmar Kovačević S, Miljković B, Radovanović S, Stevanović P. The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: a cross-sectional study. Int J Clin Pract. 2017;71(10):e13005.
Santos JC, Junior MF, Restini CBA. Potenciais interações medicamentosas identificadas em prescrições a pacientes hipertensos. Revista da Sociedade Brasileira de Cardiologia. 2012;10(4):308-17.
Brandão AA, Rodrigues CIS, Consolim-Colombo F, Plavnik FL, Malachias MVB, Kohlmann Junior O. VI diretrizes brasileiras de hipertensão. Arq Bras Cardiol. 2010;95(1):1-51. http://publicacoes.cardiol. br/
Kohlmann Jr. O, Gus M, Ribeiro AB, Vianna D, Coelho EB, Barbosa E, et al. Tratamento medicamentoso. Brazilian Journal of Nephrology. 2010;32:29-43.
Bastos, AS, Beccaria LM, Contrin, LM, Cesarino CB. Tempo de chegada do paciente com infarto agudo do miocárdio em unidade de emergência. Revista Brasileira de Cirurgia Cardiovascular/Brazilian Journal of Cardiovascular Surgery. 2012;27(3), 411-418.
Tatro SD. Drug Interaction Facts. Facts & Comparisons. 2013.
Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003;107(1):32-7.
Amaral DMD, Perassolo MS. Possíveis interações medicamentosas entre os antihipertensivos e antidiabéticos em participantes do grupo HIPERDIA de parobé, RS: uma análise teórica. Rev Cienc Farm Básica Apl. 2012;33(1):99-105.
Korolkovas A. Dicionário terapêutico Guanabara 2009/2010. 16. ed. Rio de Janeiro: Guanabara Koogan, 2009.
Almodóvar AS, Nahata MC. Associations between chronic disease, polypharmacy, and medication-related problems among Medicare beneficiaries. J Manag Care Spec Pharm. 2019;25(5):573-7.
Labarthe DR, Dunbar SB. Global Cardiovascular Health Promotion and Disease Prevention: 2011 and Beyond. Circulation.2012;125:2667-76.
Baggio MA, Erdmann AL, Higashi GDC, Koerich C, Lanzoni GMM. Descoberta da doença cardiovascular: associando causas e vivenciando o contexto da instituição hospitalar de referência. Rev Enferm UERJ. 2016;24(4):e7952.
Rodrigues MCS, Oliveira C. Interações medicamentosas e reações adversas a medicamentos em polifarmácia em idosos: uma revisão integrativa. Rev Latino-Am Enfermagem. 2016;24:e2800.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Emelli Fin Hermann, Karine Raquel Uhdich Kleibert, Paula Lorenzoni Nunes, Leila Gisleide Sehn Heck, Eliane Roseli Winkelmann, Christiane de Fátima Colet

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
A Declaração de Direito Autoral e os itens a serem observados podem ser visualizados no seguinte link: http://cascavel.ufsm.br/revistas/ojs-2.2.2/index.php/seculoxxi/information/sampleCopyrightWording
